Calabrese Joseph R, Goldberg Joseph F, Ketter Terence A, Suppes Trisha, Frye Mark, White Robin, DeVeaugh-Geiss Angela, Thompson Thomas R
Department of Psychiatry, Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio 44106, USA.
Biol Psychiatry. 2006 Jun 1;59(11):1061-4. doi: 10.1016/j.biopsych.2006.02.034.
To assess the efficacy of lamotrigine or lithium in preventing mood recurrence (i.e., a new mood episode) in bipolar disorder.
Data from bipolar I patients with relapses (i.e., mood episodes having the same polarity as the index episode within 90 or 180 days of randomization) were excluded from post hoc efficacy analyses of two 18-month, placebo-controlled maintenance trials of lamotrigine and lithium.
Both lamotrigine and lithium were more effective than placebo in delaying the time to intervention for any mood episode (depression, mania, hypomania, or mixed) when relapses that occurred in the first 90 days were excluded from the analyses (p = .002, lamotrigine vs. placebo; p = .010, lithium vs. placebo). Results were similar when patients with mood episodes within 180 days of randomization were excluded.
Both lamotrigine and lithium maintenance therapy protected against mood episode recurrence in bipolar I disorder.
评估拉莫三嗪或锂盐预防双相情感障碍患者情绪复发（即新的情绪发作）的疗效。
在两项为期18个月、以安慰剂为对照的拉莫三嗪和锂盐维持治疗试验的事后疗效分析中，排除了双相I型障碍复发患者（即在随机分组后90天或180天内出现与索引发作极性相同的情绪发作）的数据。
当分析中排除前90天内发生的复发情况时，拉莫三嗪和锂盐在延迟任何情绪发作（抑郁、躁狂、轻躁狂或混合发作）的干预时间方面均比安慰剂更有效（拉莫三嗪与安慰剂相比，p = 0.002；锂盐与安慰剂相比，p = 0.010）。当排除随机分组后180天内出现情绪发作的患者时，结果相似。
拉莫三嗪和锂盐维持治疗均可预防双相I型障碍患者的情绪发作复发。
